Activist investor Starboard Value has taken a roughly $1 billion stake in Pfizer PFE-0.08 % decrease; red down pointing triangle and wants the struggling drugmaker to make changes to turn its ...

It’s unclear what Starboard’s exact pitch will be, but people briefed on the investor’s thinking told the Financial Times that it believes Pfizer has been mismanaged in the wake of the ...

What Starboard’s Track Record With Pharma Tells Us. Story by Elsa Ohlen • 1w. A ctivist investor Starboard Value has amassed a $1 billion stake in Pfizer, according to a report, ...

Overall, Starboard’s calculation suggests the expected revenue return on R&D and M&A investments at Pfizer is just 15% between 2023 and 2030, far below the industry peer median of 38%.

The fight between Starboard Value and drug giant Pfizer PFE-0.21%decrease; red down pointing triangle took an unusual, bitter turn Thursday. Hours after two former top Pfizer executives said they ...

Activist investor Starboard Value claims the pharma giant’s former CEO and CFO were ‘threatened’ into backing current management Last Updated: Oct. 10, 2024 at 1:09 p.m. ET First Published ...

Starboard Value has taken a stake in Pfizer, people familiar with the matter said. The drug giant's stock price has dropped significantly since the rollout of its COVID-19 vaccine.

Activist hedge fund Starboard has taken a stake in drug giant Pfizer. Starboard execs met with company officials last week to outline their complaints. See highlights from the 74-page slideshow ...

Pfizer's stock surged more than 4% Monday morning after reports that activist investor Starboard Value had taken a $1 billion stake in the pharma giant.The investor wants to help turn around the ...

Pfizer Inc.'s stock dipped 2.5% Thursday as the company's battle with activist shareholder Starboard Value heated up, after two former executives for the pharma giant said they would not support ...

Activist investor Starboard Value has amassed a $1 billion stake in Pfizer according to a report, with a turnaround in its sights. The pharmaceutical company has been struggling postpandemic to ...